DBV Technologies Data at EAACI 2016 Highlight Its Expansive

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DBV Technologies Data at EAACI 2016 Highlight Its Expansive Product Development in Food Allergies

Nine Presentations Continue to Support the Potential Use of the Viaskin ® Technology in Food Allergies

Late-breaking Oral Abstract Highlights Personalized Biomarker Modeling to Predict Allergy Sensitivity during treatment with Viaskin Peanut

MONTROUGE, France, June 1, 2016 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that data from the company's Viaskin programs, a proprietary technology platform that can deliver biologically active compounds to the immune system through the skin, will be featured in nine presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2016, taking place in Vienna, Austria, June 11 - 15, 2016.

Presentations featured at the meeting will highlight progress across DBV's clinical and scientific programs, as well as Chemistry, Manufacturing and Control (CMC) activities for Viaskin Peanut, an investigational treatment for food allergy desensitization based on Epicutaneous Immunotherapy (EPIT®).

"As DBV continues to build a differentiated food allergy franchise based on our patient- and physician-friendly approach to immunotherapy, we are excited to present data at EAACI that highlight Viaskin's cutting-edge technology and science," said Dr. Pierre Henri Benhamou , Chairman and Chief Executive Officer, DBV Technologies. "We are proud to share our latest findings in critical areas such as biomarker modeling, which we believe will help our product candidates meet our patients' individual needs through personalized monitoring."   

All abstracts for the EAACI Congress will be published online on June 10, 2016 in Allergy:  Online Library

Details for each presentation follow below.

Oral Presentations

"Prediction of Peanut-Challenge Outcome with Biomarkers" Late Breaking Oral Abstract Session (LBO) Presenter: Aurélie Peillon, DBV Technologies Date/Time: June 13 / 3:45 PM - 5:15 PM Session Title:   Determination of Severity and Treatment with Food Allergy Session Number : LB OAS 4 Location :   Lehar 4

"Unique Epigenetic Modulation by EPIT Compared to OIT in a Model of Peanut Sensitized Mice:  Sustainable GAT-3 Hypermethylation and Foxp3 Hypomethylation" Presenter:  Dr. Jorg Tost, Head of Laboratory for Epigenetics and Environment (LEE), the National Genotyping Center, Genomics Institute/CEA Date/Time:   June 12 / 10:30 AM - 12:00 PM Session Title:   Immune Mechanisms of Allergen-Specific Immunotherapy Session Number: OAS 1 Location:   OAS-Stolz 2

Poster Presentations "Characterization of Peanut Proteins on a Patch for Epicutaneous Immunotherapy (EPIT)" Presenter: Isabelle Pascal, DBV Technologies Date/Time: June 12 / 12:00 PM - 1:30 PM Session Title: Allergen immunotherapy: Vaccines and clinical cases Session Number: TPS 6 Poster Number: 682 Location: Poster Exhibition

"EPIT-Induced Tregs Suppress T-cell Proliferation in Specific and Bystander Conditions in a Model of Food Allergen Sensitized Mice" Presenter:   Dr. Benjamin Pelletier, DBV Technologies Date/Time:   June 12 / 3:30 PM - 5:00 PM Session Number: PDS 10 Poster Number: 315 Location:   PDS3 Session Title:   Mechanisms of Immunotherapy

 "EPIT is Safe and Efficacious in Filaggrin Deficient Mice Sensitized to Peanut" Presenter: Dr. Sophie Wavrin, DBV Technologies Date/Time:   June 12 / 3:30 PM - 5:00 PM Session Title:   Food Allergy:  From Mice to Men Session Number: PDS 9 Poster Number: 300 Location:   PDS2

"EPIT-induced Bystander Effect Mainly Conferred by Naïve Tregs via Soluble Factors and Cell-Cell Contact in a Murine Model" Presenter: Dr. Lucie Mondoulet, DBV Technologies Date/Time:   June 12 / 3:30 PM - 5:00 PM Session Title:   Mechanisms of Immunotherapy Session Number: PDS 10 Poster Number: 313 Location :  PDS3

"Development and Validation of a Sandwich Enzyme-Linked Immunosorbent Assay (ELISA) for the Quantification of Ara h6 in Peanut Extract, and Peanut Protein Patches for Epicutaneous Immunotherapy (EPIT)" Presenter:   Isabelle Pascal, DBV Technologies Date/Time: June 12 / 3:30 PM - 5:00 PM Session Title: Mechanisms of Immunotherapy Session Number: PDS 10 Poster Number: 319 Location: PDS3

"Epicutaneous Immunotherapy but not Oral Immunotherapy Prevents Eosinophilic Infiltration in the Esophagus in a Model of Milk Sensitized Mice" Presenter: Dr. Lucie Mondoulet, DBV Technologies Date/Time:   June 13 / 10:45 AM - 12:15 PM Session Title:   Innovations in Allergen-Specific Immunotherapy Session Number: PDS 12 Poster Number: 340 Location: PDS2

"Gut Homing Receptors Designate Epicutaneous Immunotherapy as the Most Appropriate Route for the Treatment of Food Allergy in a Model of Peanut Sensitized Mice" Presenter:  Dr. Vincent Dioszeghy, DBV Technologies Date/Time:   June 13 / 10:45 AM - 12:15 PM Session Title:   Innovations in Allergen Specific Immunotherapy Session Number: PDS 12 Poster Number: 338 Location:   PDS2

About DBV Technologies  DBV Technologies developed Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.

DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

Forward Looking Statements This press release contains forward-looking statements, including statements about the potential safety and efficacy of Epicutaneous Immunotherapy (EPIT®) via Viaskin®.  These forward-looking statements that are not promises or guarantees and involve substantial risks and uncertainties. The Company's product candidates have not been approved for sale in any jurisdiction. Among the factors that could cause actual results to differ materially from those described or projected herein are uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers, the Company's Securities and Exchange Commission filings and reports, including in the Company's Annual Report on Form 20-F for the year ended December 31, 2015 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.

DBV Technologies Contacts
Susanna Mesa Senior Vice President, Strategy Tel. : +1 212-271-0861 susanna.mesa@dbv-technologies.com  
DBV Technologies Media Contacts US & Europe 
Marion Janic Rooney & Associates Tel. : +1-212-223-4017 mjanic@rooneyco.com Caroline Carmagnol Alize RP - Relation Presse Tel. : +33(0)6 64 18 99 59 caroline@alizerp.com

Erinn White Centron PR Tel. : +1-646-722-8822 ewhite@centronpr.com

PDF Version http://hugin.info/156437/R/2016959/748258.pdf

HUG#2016959

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Unisys Opens Its 2027 Innovation Program Across India

Updated Category News Views 86

Talent pipelines rarely make the market’s pulse race, but they can expose whether a tech firm is still trying to build for the next turn. Unisys has opened registration for the 2027 Unisys Innovation Program, its eighteenth annual technical competition for engineering students in India. For a company selling cloud, AI, digital workplace, applications and enterprise...

Continue Reading
Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 103

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
Midea's Cooling Systems Take Center Stage at DCW ME

Updated Category News Views 69

AI Surge Demands Cooler Solutions Alright, who'd guess that data centers would feel the heat—literally—like a welder's furnace in Abu Dhabi? As AI demand burns hotter across the Middle East, data centers are sweating it out against 50°C-plus temperatures. We're talking about some serious pressure on traditional cooling methods that just can’t cut it anymore....

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 207

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 255

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Unilumin's APEC 2026 Showcase Is a Useful Field Test

Updated Category News Views 0

Few sales pitches get stress-tested by a thousand journalists, a major airport, and a leaders' summit all at once. That is the useful part of Unilumin's role as an official sponsor of APEC 2026 in Shenzhen. The company says its LED systems were installed across summit venues, the media center, transportation hubs, and city landmarks as the 33rd APEC Economic Leaders'...

Continue Reading
Vusion Lands a 2,000-Store dm EdgeSense Rollout in Germany

Updated Category News Views 41

A drugstore shelf rarely gets anyone's pulse racing, but 2,000 of them wired into a live digital system is a serious retail deployment. Vusion has expanded its partnership with dm-drogerie markt to roll out its newest EdgeSense platform across about 2,000 German stores over the next three years. This is not a glossy one-store pilot with a ribbon-cutting and a few tablets...

Continue Reading
TIER IV Simplifies Autonomous Driving with CARLA 1.0

Updated Category News Views 63

No More Detours in Autonomous Development Ever messed with a puzzle that just won't fit until suddenly, it clicks? That's what TIER IV just pulled off with their latest work on CARLA 1.0, the open-source simulator. There's no more mucking about with that separate Python-based bridge to get things communicating—now we're talking native Autoware support. A direct line to...

Continue Reading
SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 63

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading
Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 291

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading

Top 5 Most Recently Viewed Articles

Lockheed Martin F-35 Production: Secretary's Inspiring Visit

Updated Category News Views 133

Secretary Visits Lockheed Martin's F-35 Production Facility Lockheed Martin (NYSE: LMT) proudly hosted the Secretary of War Pete Hegseth at its F-35 Lightning II production facility. This important visit highlighted the company's pivotal role in transforming defense acquisition processes. It also emphasized Lockheed Martin's dedication to delivering essential capabilities...

Continue Reading
OneAmerica Financial Foundation Empowers Caregiving Awareness

Updated Category News Views 220

OneAmerica Financial Foundation Supports Vital Caregiving Documentary The OneAmerica Financial Foundation has embarked on a significant journey by sponsoring an enlightening documentary titled "Caregiving." This compelling film delves into the experiences of caregivers, both professional and personal, across the United States. The documentary, narrated by Emmy...

Continue Reading
Multiconsult's Q2 2026: Profitability Rebounds

Updated Category News Views 26

Multiconsult's Financial Figures Take a Turn for the Better Times are looking up for Multiconsult ASA, a solid engineering firm based in Oslo. Their performance in the second quarter of 2026 spawned a tale of boosted revenues and healthier profitability. The crew isn't just resting on its laurels, as they're plugged into strategies that are set to carry them beyond 2026....

Continue Reading
KFC Revamps Menu with Original Honey BBQ and Classic Deals

Updated Category News Views 300

KFC's Exciting Revival: The Return of Iconic Flavors KFC has taken a bold step forward in its comeback era, reintroducing beloved menu items that fans have been eagerly awaiting. This time, the spotlight shines on the return of the highly sought-after Original Honey BBQ flavor. This mouthwatering sauce, which first won hearts in the late 1990s, will be back on October...

Continue Reading
Maxeon Solar Technologies Reports Financial Results for 2024

Updated Category News Views 262

Maxeon Solar Technologies Unveils Financial Outcomes for 2024 Maxeon Solar Technologies, Ltd. (NASDAQ: MAXN) has recently shared its financial results for the fourth quarter and entire fiscal year 2024, highlighting revenue reaching an impressive $509 million. The company faced significant challenges due to restrictions imposed by U.S. Customs and Border Protection (CBP)...

Continue Reading